The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

@article{KochHenriksen2009TheCE,
  title={The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.},
  author={Nils J Koch-Henriksen and Per Soelberg Sorensen and Klaus Bendtzen and Esben Meulengracht Flachs},
  journal={Multiple sclerosis},
  year={2009},
  volume={15 5},
  pages={
          601-5
        }
}
OBJECTIVE To establish whether the clinical effect of neutralizing antibodies (NAbs) against interferon-beta (IFN beta) depends on the type of IFNbeta (1a or 1b) used for treatment of patients with relapsing-remitting multiple sclerosis (MS). INTRODUCTION NAbs against IFN beta-1b appear faster and may be more evenly distributed on IgG subclasses, whereas NAbs against IFN beta-1a develop more slowly and may be devoid of IgG3. This might cause different clinical responses to NAbs. DESIGN… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Gender differences in multiple sclerosis epidemiology and treatment response.

  • Danish medical journal
  • 2016
VIEW 5 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

Thor Ameri Chalmer, Tomas Kalincik, Bjarne Laursen, Per Soelberg Sørensen, Melinda Magyari
  • Journal of Neurology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

tralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS

C Gneiss, P Tripp, F Reichartseder
  • Neurology
  • 2006